Lv3
260 积分 2022-01-06 加入
非小细胞肺癌新辅助治疗疗效病理评估专家共识
14小时前
已完结
Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?
5天前
已完结
Bispecific antibodies: advancing precision oncology
9天前
已完结
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
10天前
已完结
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
1个月前
已完结
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
1个月前
已完结
Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class
1个月前
已完结
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
1个月前
已完结
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
2个月前
已完结
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study
2个月前
已完结
皖公网安备34019202002308
